The overall cancer death rate declined by 29% from 1991 to 2017, with a 2.2% decline from 2016 to 2017 serving as the largest single-year drop in reported cancer mortality, according to research published today; however, obesity-related cancer deaths are rising and prostate cancer deaths remain stagnant.
The overall cancer death rate declined by 29% from 1991 to 2017, with a 2.2% decline from 2016 to 2017 serving as the largest single-year drop in reported cancer mortality, according to research published today in CA: A Cancer Journal for Clinicians; however, obesity-related cancer deaths are rising and prostate cancer deaths remain stagnant.
Cancer remains the second leading cause of death in the United States, with researchers from the American Cancer Society predicting the disease will affect more than 1.7 million people and cause 600,000 deaths in the nation this year. Overall cancer mortality has seen an average drop of 1.5% per year in the last decade (2008-2017), with the steady decline from 1991 translating to approximately 2.9 million fewer cancer deaths.
The decline can be attributed to long-term drops in death rates for the 4 major cancers—lung, colorectal, breast, and prostate. Lung cancer mortality rates, which constitute a quarter of all cancer deaths, represent a chief influence on the historic decline in cancer mortality, as the pace of mortality reductions has doubled in recent years from 2% to 4%, with further significant declines made over the long term among the other 3 major cancers:
Progress in treatment for melanoma of the skin drove the most rapid death rate decline seen in the research, as the overall melanoma death rate dropped by 7% per year during 2013-2017 in people aged 20 to 64 years. Prior to the FDA approval of 2 melanoma treatments, ipilimumab and vemurafenib, these death rates decreased by 2% to 3% each year among people aged 20 to 49 years, with a minimal decline of 1% in those aged 50 to 64 years. Since 2010, the 1-year survival for patients diagnosed with metastatic disease rose from 42% (2008-2010) to 55% during 2013-2015.
While these long-term declines show promise, reductions in death rates slowed for female breast and colorectal cancers, and halted for prostate cancer, causing lead study author Rebecca Siegel, MPH, scientific director of Surveillance Research at the American Cancer Society, to describe the significance of the study findings as mixed.
Furthermore, cancers that exhibited increases in death rates, such as thyroid, pancreas, and uterus, were all linked to obesity, stressing the public health crisis caused by the obesity epidemic. As African American (46.8%) and Hispanic (47%) adults were shown to be disproportionately affected by obesity, these minority groups represent definite at-risk groups.
“It’s a reminder that increasing our investment in the equitable application of existing cancer control interventions, as well as basic and clinical research to further advance treatment, would undoubtedly accelerate progress against cancer,” said Siegel.
Reference
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020 [published online January 8, 2019]. CA Cancer J Clin. doi: 10.3322/caac.21590.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Similar In-Hospital, Long-Term Survival Rates Found Among Male, Female Patients With AECOPD
March 18th 2024This study analyzed sex differences among patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), with findings indicating that female smokers experience worse hospital outcomes despite similar overall survival rates.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
AstraZeneca joins efforts to address high drug prices by capping out-of-pocket costs for its inhalers; Opill, the first OTC birth control pill, is now accessible through online sales; expansion prompts questions on the effectiveness and regulation of remote monitoring technology.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Similar In-Hospital, Long-Term Survival Rates Found Among Male, Female Patients With AECOPD
March 18th 2024This study analyzed sex differences among patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), with findings indicating that female smokers experience worse hospital outcomes despite similar overall survival rates.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
AstraZeneca joins efforts to address high drug prices by capping out-of-pocket costs for its inhalers; Opill, the first OTC birth control pill, is now accessible through online sales; expansion prompts questions on the effectiveness and regulation of remote monitoring technology.
Read More
2 Commerce Drive
Cranbury, NJ 08512